Google+ Badge

Wednesday, January 07, 2015

UPDATED 01/07/2015 : New Analysis Challenges Tamiflu Efficacy; Hong Kong Corona Virus Outbreak

UPDATED 01/07/2015

FOX NEWS CORPORATE PHARMA SHILL MEGAN KELLY AND FOX NEWS QUACK DOCTOR NOW PUSHING TAMIFLU FOR PREGNANT WOMEN AND CHILDREN; 

THE 5TH ESTATE UNEQUIVOCALLY WARNS THE PUBLIC NOT TO TAKE OR GIVE THIS PROVEN DANGEROUS, INEFFECTIVE DRUG TO ANYONE

Obama criminals now resulting to biowarfare in quest to destroy Chinese and ASEAN economy; "novel virus substrain" points directly to a Kawaoka/Fouchier/Ernala-Ginting Kobe lab virus weaponized and genetically altered to specifically target and infect the Asian population:  Ribavirin remains the only known drug at this time that will slow the viral load of these weaponized corona viruses and should also be considered as a prophylaxis for anyone flying through affected countries

The 5th Estate recommends readers now avoid Tamiflu completely, for the obvious reason that it has the propensity to cause severe side-effects and the primary reason that it simply does not work;

Ribavirin appears now to be the only drug that will slow weaponized coronaviruses like H5N1 and MERS;

The below story appears to be a propaganda piece to place doubt on a known anti-viral (despite it's nasty side effects) as it is now evident the new "novel" weaponized H5N1 from Kobe University courtesy of Teridah Ernala and Kawaoka has already been intentionally released; Ernala's propaganda website Bird Flu Corner shut down on January 12, following the publication of the exclusive 5th Estate reports on Kobe University creation of novel H5N1 in an illegal lab by Ernala under Kawaoka

MEDPAGE TODAY
By Michael Smith, North American Correspondent, MedPage Today
Published: January 17, 2012

Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco

A new review of the influenza drug oseltamivir (Tamiflu) has raised questions about both the efficacy of the medication and the commitment of its maker to supply enough data for claims about the drug to be evaluated by independent experts.


Kobe University's Yoshihiro Kawaoka and Teridah Ernala Ginting
It also raises questions about the entire process of systematic review. Researchers led by Tom Jefferson, MD, of the Cochrane Collaboration, pored over 15 published studies and nearly 30,000 pages of "clinical study reports."

But, they reported, the clinical study information – data previously shared only with regulators – was only a part of what internal evidence suggested was available.


And many published studies had to be excluded because of missing or contradictory data, Jefferson and colleagues reported.

Action Points

Explain that a new review of an important flu drug has raised questions about the medication and the entire process of systematic review.

Point out that the review of oseltamivir showed that there was no evidence of effect on hospital admissions.

The drug's maker, Switzerland-based Roche, had promised after a previous Cochrane review to make all of its data available for "legitimate analyses." After a request for the data, Jefferson and colleagues reported, the company sent them 3,195 pages covering 10 treatment trials of the drug.

But, three of the reviewers noted in a parallel report in BMJ, the tables of contents suggested that the data were incomplete.

"What we're seeing is largely Chapter One and Chapter Two of reports that usually have four or five chapters," according to the BMJ article's lead author, Peter Doshi, PhD, of Johns Hopkins University.

Roche did not immediately respond to a telephoned request for comment.

Requests for More Data


H5N1
The researchers then asked the European Medicines Agency (EMA) for the data, under a Freedom of Information request, and obtained a further 25,453 pages, covering 19 trials. But that data, too, was incomplete, they said, although the agency said it was all that was available.


The FDA is thought to have the complete reports, but has not yet responded to requests for them, the researchers reported.

Regulatory agencies such as the EMA and FDA routinely see the large clinical study reports, Jefferson and colleagues said in BMJ, but systematic reviewers and the general medical public do not.

"While regulators and systematic reviewers may assess the same clinical trials, the data they look at differs substantially," they said.

The Cochrane group has been trying for several years to put together a clear-cut systematic review of the evidence on antivirals aimed at flu.

In 2006, the group concluded that the evidence showed that oseltamivir reduced the complications of the flu. But that conclusion was challenged on the basis that a key piece of data was flawed.

An updated review in 2009 – throwing out the flawed study -- concluded there wasn't enough evidence to show that the drug had any effect on complications.

For this analysis, the Cochrane reviewers had originally intended to perform a systematic review on both of the approved neuraminidase inhibitors – oseltamivir and zanamivir (Relenza), using the clinical study reports to supplement published trials.

In the end, they decided that for oseltamivir, they needed more detail in order to perform the review in its entirety. But, they reported, some conclusions could be drawn from published data on the 15 trials and from 16,000 pages of clinical study reports that were available before their deadline.

They also decided to postpone analysis of zanamivir (for which they had 10 trials) because the drug's maker, GlaxoSmithKline, offered individual patient data which they wanted time to analyze.

The oseltamivir analysis showed:


Tamiflu should not be taken by anyone under any circumstances
 The time to first alleviation of symptoms in people with influenza-like illness was a median of 160 hours in the placebo groups and about 21 hours shorter in those treated with oseltamivir.

The difference, evaluated in five studies, was significant at P<0.001. There was no evidence of effect on hospital admissions.



In seven studies, the odds ratio was 0.95, with a 95% confidence interval from 0.57 to 1.61, which was nonsignificant at P=0.86.

A post-protocol analysis of eight studies showed that oseltamivir patients were less likely to be diagnosed with influenza. The data "lacked sufficient detail to credibly assess" any effect on influenza complications and viral transmission.

Data Discrepancies Found

But discrepancies between the published trial data and the clinical study reports "led us to lose confidence in the journal reports," Doshi and colleagues wrote in BMJ.

For example, they noted that one journal report clearly said there were no drug-related serious adverse events, but the clinical study report listed three that were possibly related to oseltamivir.

As well, the sheer scope of the clinical study reports meant that much was left out of journal reports.

One 2010 study, on safety and pharmacokinetics of oseltamivir at standard and high dosages, took up seven journal pages and 8,545 pages of the clinical study report.

But the researchers were also shaken, they said, by the "fragility" of some of their assumptions.

For instance, they found that the clinical study reports showed that in many trials, the placebo contained two chemicals not found in the oseltamivir capsules.

"We could find no explanation for why these ingredients were only in the placebo," they wrote in BMJ, "and Roche did not answer our request for more information on the placebo content."

Jefferson and colleagues also reported they found disparities in the numbers of influenza-infected people reported to be present in the treatment versus control groups of oseltamivir trials.

One possible explanation, they noted, is that oseltamivir affects antibody production – even though the manufacturer says it does not.

Gaps in Knowledge Remain

That question is profoundly important, Doshi told MedPage Today, because it may offer clues to how the drug works – one of the gaps in knowledge about oseltamivir.


Over years Ernala revealed in e-mails her work to The 5th Estate
Over years Ernala revealed in e-mails her work to The 5th Estate "You can't make good therapeutic decisions if you don't know how the drugs works," he said – information that he and his colleagues suspect may be buried in the mass of missing data. It's also important, he said, because public health agencies have been making decisions to stockpile oseltamivir without a clear understanding of the facts.


Essentially, he said, those decisions have been based on the flawed study – a Roche-supported meta-analysis – that was thrown out of the 2009 Cochrane review.

"They're taking the drug manufacturer's word at face value," he said.

The results seem unlikely to resolve conflicts over the medical value of the drug, which is a major cash cow for Roche, adding some $3.4 billion to the company's bottom line in 2009 alone, according to Deborah Cohen, investigations editor of BMJ.

In an accompanying article, Cohen said that "clinicians can be forgiven for being confused about what the evidence on oseltamivir says."

She noted that the European Centre for Disease Prevention and Control, the CDC, and the World Health Organization "differ in their conclusions about what the drug does."

As well, those conclusions are often contradicted by claims on the drug labels – themselves allowed by regulators, Cohen argued.

The Cochrane reviewers reported grant support from the U.K. National Institute for Health Research and Jefferson and Doshi reported they had no recent financial links with industry.

Cohen is employed by BMJ.

Primary source: Cochrane Database of Systematic Reviews

Source reference:

Additional source: BMJ
Source reference:

Additional source: BMJ
Source reference:




This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.

-------------------------------------------------------------------------------------------------------------------

ANDREW KREIG: EXPERTS REJECT FIRE AS CAUSE FOR 9/11 WTC COLLAPSES

The real truth on 9/11 slowly continues to bleed out

 photo
Technical experts are mounting major challenges to official U.S. government accounts of how three World Trade Center skyscrapers collapsed in near-freefall after the 9/11 attacks 15 years ago.

Many researchers are focusing especially on the little-known collapse of

READ MORE >>

-------------------------------------------------------------------------------------------------------------------

The Geopolitics Of The United States, Part 1: The Inevitable Empire

The Empire and the inevitable fall of the Obama criminal regime

 photo
STRATFOR Editor’s Note: This installment on the United States, presented in two parts, is the 16th in a series of STRATFOR monographs on the geopolitics of countries influential in world affairs.

Like nearly all of the peoples of North and South America, most Americans are not originally from the territory that became the United States.

READ MORE >>

-------------------------------------------------------------------------------------------------------------------

Geopolitics Of The United States Part 2: American Identity And The Threats of Tomorrow

A look back at 2011 predictions for the future in order to put events of today into perspective

 photo capitalism_zpsah78uy5p.jpg
We have already discussed in the first part of this analysis how the American geography dooms whoever controls the territory to being a global power, but there are a number of other outcomes that shape what that power will be like. The first and most critical is the impact of that geography on the American mindset.

READ MORE >>

-------------------------------------------------------------------------------------------------------------------


By Robert S. Finnegan

This e-mail outlines and confirms the acts of espionage against Indonesia and Indonesians by Akiko Makino and the others involved both in Kobe University and in AI Lab at University of Airlangga, Surabaya; Bahasa Indonesia original follows English translation...

READ MORE >>

-------------------------------------------------------------------------------------------------------------------

UPDATED 01/07/2015 : New Analysis Challenges Tamiflu Efficacy; Hong Kong Corona Virus Outbreak

UPDATED 01/07/2015 : FOX NEWS CORPORATE PHARMA SHILL MEGAN KELLY AND FOX NEWS QUACK DOCTOR NOW PUSHING TAMIFLU FOR PREGNANT WOMEN AND CHILDREN;

 photo TAMIFLU_small_zpssojx6okt.jpg
THE 5TH ESTATE UNEQUIVOCALLY WARNS THE PUBLIC NOT TO TAKE OR GIVE THIS PROVEN DANGEROUS, INEFFECTIVE DRUG TO ANYONE

Obama criminals now resulting to biowarfare in quest to destroy Chinese and ASEAN economy; "novel virus substrain" points directly to a Kawaoka / Fouchier / Ernala-Ginting Kobe lab virus weaponized and genetically altered to specifically target and infect the Asian population: Ribavirin...

READ MORE >>

-------------------------------------------------------------------------------------------------------------------


 photo WHO02_zpsplmhtlpr.jpg
The 5th Estate has just purchased a library on H5N1 "Novel" virus pandemics, there are dozens of PDF and Exel documents we feel will assist you in saving lives following intentional releases of the H5N1 and now MERS viruses; we will begin by printing those that appear to be extremely relevant here: H5N1 Kobe-Kawaoka-Ernala series continues soon with more "Smoking Gun" e-mails from Teridah Ernala to The 5th Estate . . .

READ MORE >>

-------------------------------------------------------------------------------------------------------------------


By Robert S. Finnegan

On October 12, 2002 the Indonesian island of Bali experienced a terrorist attack that rocked the world. It was unquestionably well-coordinated and executed, the largest in the country's history.

READ MORE >>